[HTML][HTML] Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies

S Xu, I Ilyas, J Weng - Acta Pharmacologica Sinica, 2023 - nature.com
The fight against coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is
still raging. However, the pathophysiology of acute and post-acute manifestations of COVID …

[HTML][HTML] The signal pathways and treatment of cytokine storm in COVID-19

L Yang, X Xie, Z Tu, J Fu, D Xu, Y Zhou - Signal transduction and …, 2021 - nature.com
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …

[HTML][HTML] IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines

S Tahtinen, AJ Tong, P Himmels, J Oh… - Nature …, 2022 - nature.com
The use of lipid-formulated RNA vaccines for cancer or COVID-19 is associated with dose-
limiting systemic inflammatory responses in humans that were not predicted from preclinical …

[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …

E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis… - Nature medicine, 2021 - nature.com
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …

[HTML][HTML] Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)

A Aleem, AS Ab, AK Slenker - 2021 - europepmc.org
Objectives: Describe the clinical manifestations, including extrapulmonary manifestations of
COVID-19. Outline the latest treatments available in the management of COVID-19 …

[HTML][HTML] Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

EC Morris, SS Neelapu, T Giavridis… - Nature Reviews …, 2022 - nature.com
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …

[HTML][HTML] The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

MF Osuchowski, MS Winkler, T Skirecki… - The Lancet …, 2021 - thelancet.com
The zoonotic SARS-CoV-2 virus that causes COVID-19 continues to spread worldwide, with
devastating consequences. While the medical community has gained insight into the …

[HTML][HTML] Inflammasome activation at the crux of severe COVID-19

SM Vora, J Lieberman, H Wu - Nature Reviews Immunology, 2021 - nature.com
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), results in life-threatening disease in a minority of patients, especially elderly …

[HTML][HTML] Cytokine storm in COVID-19: immunopathogenesis and therapy

C Zanza, T Romenskaya, AC Manetti, F Franceschi… - Medicina, 2022 - mdpi.com
A cytokine storm is a hyperinflammatory state secondary to the excessive production of
cytokines by a deregulated immune system. It manifests clinically as an influenza-like …

[HTML][HTML] Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy

Q Zhang, R Xiang, S Huo, Y Zhou, S Jiang… - Signal transduction and …, 2021 - nature.com
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …